Yamamoto Yutaka

ヤマモトユタカ | Yamamoto Yutaka

Affiliation and department：
Job title： Associate Professor
Homepage URL (1)： http://www2.kuh.kumamoto-u.ac.jp/breast/

Research field (1)： General surgery, pediatric surgery

Research keywords (3)： clinical trials , 乳癌の生物学的因子 , Biological factors for breast cancer

Research theme for competitive and other funds (5)：

2014 - 2017 Detection for predictive factors of estrogen addition and depletion therapy in endocrine therapy-resistant breast cancer
2012 - 2015 Development of quantitative evaluation tool using multigene expression to predict efficacy of endocrine therapy for breast cancer
2012 - 2015 The role of MACC1 in breast cancer
2009 - 2011 Study for mechanism of cell cycle regulation by ubiquitin ligase in triple-negative breast cancer
2007 - 2008 The study on the sensitization of transcriptional modulator to endocrine therapy for breast cancer

Papers (168)：

Masaya Hattori, Naoko Honma, Shigenori Nagai, Kazutaka Narui, Tomoko Shigechi, Yukinori Ozaki, Masayuki Yoshida, Takashi Sakatani, Eiichi Sasaki, Yuko Tanabe, et al. Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines. Breast cancer (Tokyo, Japan). 2024
Takehiko Sakai, Goro Kutomi, Tadahiko Shien, Sota Asaga, Tomoyuki Aruga, Makoto Ishitobi, Sayaka Kuba, Masataka Sawaki, Kaori Terata, Koichi Tomita, et al. The Japanese Breast Cancer Society Clinical Practice Guidelines for surgical treatment of breast cancer, 2022 edition. Breast cancer (Tokyo, Japan). 2023
Kenichi Watanabe, Naoki Niikura, Yuichiro Kikawa, Mari Oba, Kokoro Kobayashi, Hiroshi Tada, Shinji Ozaki, Uhi Toh, Yutaka Yamamoto, Michiko Tsuneizumi, et al. Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial). Breast cancer research and treatment. 2023. 199. 2. 253-263
Hiroji Iwata, Yutaka Yamamoto, Takehiko Sakai, Yoshie Hasegawa, Rikiya Nakamura, Hiromitsu Akabane, Shoichiro Ohtani, Masahiro Kashiwaba, Naruto Taira, Tatsuya Toyama, et al. Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy. Breast cancer research and treatment. 2023. 199. 2. 231-241
Yoshihiro Komohara, Daisuke Kurotaki, Hirotake Tsukamoto, Yuko Miyasato, Hiromu Yano, Cheng Pan, Yutaka Yamamoto, Yukio Fujiwara. Involvement of protumor macrophages in breast cancer progression and characterization of macrophage phenotypes. Cancer science. 2023

ｍore...

MISC (362)：

菰原義弘, 新地祐介, 米満侯宏, 藤原章雄, 山本豊, 鈴木実. The mechanisms of PD-L1 overexpression in tumor associated macrophages (TAMs) in lung and breast cancers. 日本癌学会学術総会抄録集(Web). 2022. 81st
Akihiko Shimomura, Masayuki Nagahashi, Hiraku Kumamaru, Yutaka Yamamoto, Hiromitsu Jinno, Shigeru Imoto. Clinicopathological characteristics of male breast cancer in Japan from the national clinical database. CANCER RESEARCH. 2021. 81. 4
Yutaka Yamamoto, Hiroji Iwata, Taira Naruto, Norikazu Masuda, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Tatsuya Toyama, Takashi Yamanaka, Toshimi Takano, et al. A randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study. CANCER RESEARCH. 2021. 81. 4
稲尾瞳子, 日高香織, 藤川和晃, 後藤理沙, 冨口麻衣, 末田愛子, 山本豊. 術前診断が困難であった甲状腺充実型乳頭癌の一例. 乳腺甲状腺超音波医学. 2021. 10. 4
安立弥生, 麻賀創太, 隈丸拓, 山本豊, 神野浩光. NCD乳癌登録を用いたInvasive lobular carcinomaのサブタイプ別の予後に関する研究. 日本乳癌学会総会プログラム抄録集. 2020. 28回. 49-49

ｍore...

Books (18)：

乳腺腫瘍学第3版
金原出版 2020 ISBN:9784307204088
領域横断的がん取扱い規約
金原出版 2019 ISBN:9784307004862
臨床・病理乳癌取扱い規約
金原出版 2018 ISBN:9784307203869
乳がん薬物療法ハンドブック
南江堂 2018
乳がん薬物療法副作用マネジメントプロのコツ
メディカルレビュー社 2017

ｍore...

Lectures and oral presentations (111)：

地震災害から得られた教訓 -乳癌診療を通じて-
(第18回日本臨床腫瘍学会学術集会 2021)
Optimal sequential endocrine treatment with targeted therapies in postmenopausal ER-positive/HER2-negative advanced breast cancer
(KYOTO BREAST CANCER CONSENSUS CONFERENCE 2021 2021)
A randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study
(43rd Annual San Antonio Breast Cancer Symposium 2020)
Pooled-analysis of prospective observational studies evaluated the effectiveness and safety of bevacizumab and paclitaxel as the first-line chemotherapy for HER2-negative metastatic breast cancer.
(2020)
乳癌におけるリキッドバイオプシーの現状と将来展望
(第32回日本内分泌外科学会総会 2020)

ｍore...

Works (1)：

転写モジュレーターによる乳癌内分泌療法の効果増強に関する研究
2007 - 2008

Education (1)：

1985 - 1991 Miyazaki Medical College Department of Medicine

Professional career (1)：

Doctor of Medicine (Kumamoto University)

Work history (12)：

2022/04 - 現在 Kumamoto University Hospital Department of Breast and Endocrine Surgery Professor
2021/10 - 現在 Graduate School of Medical Sciences, Kumamoto University Department of Respiratory Surgery and Breast Surgery Associate Professor
2015/04 - 2021/10 Graduate School of Medical Sciences, Kumamoto University Department of Breast and Endocrine surgery Associate Professor
2012 - 2015 熊本大学医学部附属病院乳癌分子標的治療学寄附講座寄附講座教員
2015 - Kumamoto University Faculty of Life Sciences

Show all

Committee career (19)：

2020/09 - 現在 Japan Breast Cancer Society Future Planning Committee
2020/09 - 現在 Japan Breast Cancer Society Insurance Covered Medical Treatments Committee
2020/09 - 現在 Japan Breast Cancer Society Academic Committee
2016/08 - 現在日本乳癌学会専門医制度委員会
2016/08 - 現在日本乳癌学会理事(外科系)

Show all

Association Membership(s) (2)：

日本乳癌学会 , The Japanese Breast Cancer Society

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page